Vaccine answers for doctors

Latest developments 

We hope that the following information answers some of those questions as BC’s Immunization Plan continues across our province.

Please note that the information on this web page is based on updates from the BCCDC, the Provincial Health Officer, and the provincial government.

Attestation form: Third doses for CEV patients (group 2)

Doctors are to use the form if this group of CEV patients has not received a call from public health staff by Friday, October 8. The form includes information to identify patients with conditions who are eligible for the third dose.

Qs and As: Third doses for CEV patients (group 1 and 2)

This Q and A addresses third dose planning for clinically extremely vulnerable – moderately to severely immunocompromised populations (groups 1 & 2).

BCCDC information on third doses for groups 1 and 2 patients  (link is external)

Information on third doses for clinically extremely vulnerable patients from the BCCDC web site. This can be shared with patients who may have questions.

Third dose of COVID-19 vaccine available for severely immunocompromised(link is external)

The BC Centre for Disease Control has announced the first group of severely immunocompromised patients that will receive a third dose of COVID-19 vaccine.  

Attestation form for third dose COVID-19 vaccine

This attestation form is for the first group of severely immunocompromised patients who are eligible to receive a third dose of COVID-19 vaccine. List of conditions is contained in the form. 

Infection prevention and control guidelines: Summary for physicians with community practices

Statement from the College, Ministry of Health, and Provincial Health officer on in-person and virtual care(link is external)

The statement provides updated guidance to community physicians on in-person and virtual care.


Do you have questions that are not included on this page? Email us at .

We will regularly update and share common questions and answers as new information becomes available.